We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) closed the most recent trading day at $9.52, moving -1.86% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.03%. Elsewhere, the Dow saw a downswing of 0.31%, while the tech-heavy Nasdaq appreciated by 0.01%.
The infectious disease drug developer's stock has climbed by 0.73% in the past month, exceeding the Medical sector's loss of 4.15% and the S&P 500's gain of 0.53%.
Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure. On that day, Adma Biologics is projected to report earnings of $0.19 per share, which would represent year-over-year growth of 18.75%. Simultaneously, our latest consensus estimate expects the revenue to be $139.8 million, showing a 4.16% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.78 per share and revenue of $536.82 million, indicating changes of +30% and +5.22%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Adma Biologics. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Adma Biologics is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Adma Biologics is holding a Forward P/E ratio of 12.49. Its industry sports an average Forward P/E of 25.2, so one might conclude that Adma Biologics is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 174, positioning it in the bottom 30% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today
Adma Biologics (ADMA - Free Report) closed the most recent trading day at $9.52, moving -1.86% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.03%. Elsewhere, the Dow saw a downswing of 0.31%, while the tech-heavy Nasdaq appreciated by 0.01%.
The infectious disease drug developer's stock has climbed by 0.73% in the past month, exceeding the Medical sector's loss of 4.15% and the S&P 500's gain of 0.53%.
Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure. On that day, Adma Biologics is projected to report earnings of $0.19 per share, which would represent year-over-year growth of 18.75%. Simultaneously, our latest consensus estimate expects the revenue to be $139.8 million, showing a 4.16% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.78 per share and revenue of $536.82 million, indicating changes of +30% and +5.22%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Adma Biologics. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Adma Biologics is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Adma Biologics is holding a Forward P/E ratio of 12.49. Its industry sports an average Forward P/E of 25.2, so one might conclude that Adma Biologics is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 174, positioning it in the bottom 30% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.